Page last updated: 2024-12-06

3-hydroxybenzo(a)pyrene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-hydroxybenzo(a)pyrene: RN given refers to unlabeled parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25890
CHEMBL ID8020
CHEBI ID34337
SCHEMBL ID145489
MeSH IDM0076054

Synonyms (35)

Synonym
BIDD:ER0040
3-hydroxy benzo[a]pyrene
bp-3-hydroxy
ccris 1071
brn 2333868
benzo(a)pyrene, 3-hydroxy-
benzo(a)pyren-3-ol
3-hydroxybenzo(a)pyrene
8-hydroxy-3,4-benzpyrene
3-hydroxybenzo[a]pyrene
13345-21-6
3-oh-bap
benzo[def]chrysen-3-ol
CHEMBL8020 ,
chebi:34337 ,
3-hydroxy benzopyrene
FT-0669410
benzo[a]pyren-3-ol
4-06-00-05133 (beilstein handbook reference)
672ich1q4l ,
unii-672ich1q4l
FT-0636874
AKOS022180750
SCHEMBL145489
3-hydroxy benzo(a)pyrene
benzo(pqr)tetraphen-3-ol
hydroxybenzo(a)pyrene, 3-
SPUUWWRWIAEPDB-UHFFFAOYSA-N
3-hydroxybenz[a]pyrene
DTXSID7038319
8sk ,
bdbm50474722
Q26840846
benzo[pqr]tetraphen-3-ol
pentacyclo[10.6.2.0?,?.0?,??.0??,??]icosa-1(18),2(7),3,5,8,10,12,14,16,19-decaen-13-ol

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" A rat physiologically-based pharmacokinetic model of BaP and 3-OHBaP was built."( Understanding the linked kinetics of benzo(a)pyrene and 3-hydroxybenzo(a)pyrene biomarker of exposure using physiologically-based pharmacokinetic modelling in rats.
Bouchard, M; Heredia-Ortiz, R, 2013
)
0.64
" In the present study, we have used a human physiologically-based pharmacokinetic (PBPK) model and an simple compartmental toxicokinetic model of benzo(a)pyrene (BaP) kinetics and its 3-hydroxybenzo(a)pyrene (3-OHBaP) metabolite to reproduce the time-course of this biomarker of exposure in the urine of industrially exposed workers and in turn predict the most plausible exposure scenarios."( Use of physiologically-based pharmacokinetic modeling to simulate the profiles of 3-hydroxybenzo(a)pyrene in workers exposed to polycyclic aromatic hydrocarbons.
Barbeau, D; Bouchard, M; Heredia Ortiz, R; Lafontaine, M; MaƮtre, A, 2014
)
0.82
" A physiologically based pharmacokinetic (PBPK) model for BaP for the rat was extended to simulate inhalation exposures to BaP in rats and humans including particle deposition and dissolution of absorbed BaP and renal elimination of 3-hydroxy benzo[a]pyrene (3-OH BaP) in humans."( Predicting lung dosimetry of inhaled particleborne benzo[a]pyrene using physiologically based pharmacokinetic modeling.
Campbell, J; Clewell, H; Crowell, S; Franzen, A; Gentry, R; Loccisano, A; Lumpkin, M; Meredith, C; Van Landingham, C, 2016
)
0.43
" The time courses of BaP and 3-OHBaP were simulated by using a physiologically based pharmacokinetic model with Advanced Continuous Simulation Language (ACSLX)."( Physiologically-based pharmacokinetic modeling of benzo(a)pyrene and the metabolite in humans of different ages.
Deng, L; Deng, Q; Liu, H, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" In addition, the bioavailability of chemical components of MGP were also investigated by monitoring polycyclic aromatic hydrocarbon (PAH) metabolites in urine and DNA adduct formation in forestomach and lung tissue."( Biochemical effects of manufactured gas plant residue following ingestion by B6C3F1 mice.
Goldstein, L; Patel, S; Weyand, EH; Wu, Y, 1994
)
0.29
"The intestinal bioavailability and biotransformation of 3-hydroxybenzo(a)pyrene, a major metabolite of benzo(a)pyrene in many animal species, was investigated in an in situ isolated intestinal preparation from the channel catfish, and in vitro with preparations of catfish intestine and blood."( Intestinal bioavailability and biotransformation of 3-hydroxybenzo(a)pyrene in an isolated perfused preparation from channel catfish, Ictalurus punctatus.
James, MO; Kleinow, KM; Rowland-Faux, L; Tong, Z; Venugopal, CS, 2001
)
0.81
" As a part of ongoing research into the bioavailability of environmental pollutants in catfish intestine, we investigated the effects of a series of hydroxylated PCBs (OH-PCBs) on two conjugating enzymes, phenol-type sulfotransferase and glucuronosyltransferase."( Hydroxylated polychlorinated biphenyls as inhibitors of the sulfation and glucuronidation of 3-hydroxy-benzo[a]pyrene.
James, MO; Kubiczak, GA; Lehmler, HJ; van den Hurk, P, 2002
)
0.31
"Previous studies examined the bioavailability and first-pass biotransformation of 3-hydroxy[(3)H]benzo[a]pyrene ([(3)H]-3-OHBaP) in an isolated perfused catfish intestinal model."( Binding of 3-hydroxybenzo[a]pyrene to bovine hemoglobin and albumin.
James, MO; Sugihara, N, 2003
)
0.32

Dosage Studied

ExcerptRelevanceReference
" To verify this aspect further, the urinary excretion kinetic of 3-OHBaP following acute intraperitoneal dosing (31."( Benzo(a)pyrenediolepoxide-hemoglobin adducts and 3-hydroxy-benzo(a)pyrene urinary excretion profiles in rats subchronically exposed to benzo(a)pyrene.
Bouchard, M; Viau, C, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
ortho- and peri-fused polycyclic arene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptorOvis aries (sheep)Kd1.10000.49002.03755.9000AID69702
Estrogen receptor betaOvis aries (sheep)Kd1.10000.49002.03755.9000AID69702
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID69702Displacement of [3H]-estradiol (E2) from sheep uterine estrogen receptor2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (88)

TimeframeStudies, This Drug (%)All Drugs %
pre-199027 (30.68)18.7374
1990's19 (21.59)18.2507
2000's21 (23.86)29.6817
2010's20 (22.73)24.3611
2020's1 (1.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.51 (24.57)
Research Supply Index4.54 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.09%)5.53%
Reviews3 (3.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other88 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]